Peroxisome proliferator activated receptors and lipoprotein metabolism

PPAR Research

Volumn , Issue , 2008, Pages

  Kersten, Sander ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BILE ACID; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; ESTROGEN RECEPTOR; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; PIRINIXIC ACID; ROSIGLITAZONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DNA BINDING; DRUG EFFECT; DRUG MECHANISM; FATTY ACID OXIDATION; GENETIC TRANSCRIPTION; HUMAN; LIPID METABOLISM; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 36949009469     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/132960     Document Type: Review

References (123)

1. A. Chawla J. J. Repa R. M. Evans D. J. Mangelsdorf Nuclear receptors and lipid physiology: opening the X-files. Science 294 5548 2001 1866 1870
2. A. Aranda aaranda@iib.uam.es A. Pascual Nuclear hormone receptors and gene expression. Physiological Reviews 81 3 2001 1269 1304
3. S. Kersten B. Desvergne W. Wahli walter.wahli@iba.unil.ch Roles of PPARS in health and disease. Nature 405 6785 2000 421 424
4. I. Issemann S. Green Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 6294 1990 645 650
5. B. Desvergne W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 20 5 1999 649 688
6. S. Mandard M. Müller S. Kersten sander.kersten@wur.nl Peroxisome proliferator-activated receptor α target genes. Cellular and Molecular Life Sciences 61 4 2004 393 416
7. R. T. Nolte G. B. Wisely S. Westin Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-γ Nature 395 6698 1998 137 143
8. H. E. Xu ex11957@glaxowellcome.com M. H. Lambert V. G. Montana Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Molecular Cell 3 3 1999 397 403
9. O. Braissant F. Foufelle C. Scotto M. Dauça W. Wahli Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137 1 1996 354 366
10. C. Knouff J. Auwerx auwerx@igbmc.u-strasbg.fr Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocrine Reviews 25 6 2004 899 918
11. L. Michalik B. Desvergne N. S. Tan Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. Journal of Cell Biology 154 4 2001 799 814
12. T. Tanaka J. Yamamoto S. Iwasaki Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proceedings of the National Academy of Sciences of the United States of America 100 26 2003 15924 15929
13. M. D. Leibowitz mleibowitz@ligand.com C. Fiévet N. Hennuyer Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Letters 473 3 2000 333 336
14. M. Gottlicher E. Widmark Q. Li J. Gustafsson Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America 89 10 1992 4653 4657
15. S. S. Lee T. Pineau J. Drago Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Molecular and Cellular Biology 15 6 1995 3012 3022
16. M. H. Frick O. Elo K. Haapa Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. The New England Journal of Medicine 317 20 1987 1237 1245
17. H. B. Rubins bloom013@tc.umn.edu S. J. Robins D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. The New England Journal of Medicine 341 6 1999 410 418
18. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 1 2000 21 27
19. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. The Lancet 357 9260 2001 905 910
20. J. M. Peters N. Hennuyer B. Staels Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. Journal of Biological Chemistry 272 43 1997 27307 27312
21. C. Améen U. Edvardsson A. Ljungberg Activation of peroxisome proliferator-activated receptor α increases the expression and activity of microsomal triglyceride transfer protein in the liver. Journal of Biological Chemistry 280 2 2005 1224 1229
22. P. Costet C. Legendre J. Moré A. Edgar P. Galtier T. Pineau tpineau@toulouse.inra.fr Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. Journal of Biological Chemistry 273 45 1998 29577 29585
23. Y. A. Kesaniemi S. M. Grundy Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. Journal of the American Medical Association 251 17 1984 2241 2246
24. K. Tordjman C. Bernal-Mizrachi L. Zemany PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. Journal of Clinical Investigation 107 8 2001 1025 1034
25. D. Lindén M. Alsterholm H. Wennbo J. Oscarsson PPARα deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins. Journal of Lipid Research 42 11 2001 1831 1840
26. D. Lindén K. Lindberg J. Oscarsson Influence of peroxisome proliferator-activated receptor α agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48. Journal of Biological Chemistry 277 25 2002 23044 23053
27. M. Adiels S.-O. Olofsson M.-R. Taskinen J. Borén Jan.Boren@wlab.gu.se Diabetic dyslipidaemia. Current Opinion in Lipidology 17 3 2006 238 246
28. E. A. Fisher H. N. Ginsberg Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. Journal of Biological Chemistry 277 20 2002 17377 17380
29. M. Adiels M.-R. Taskinen C. Packard Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49 4 2006 755 765
30. C. H. Wiegman R. H. J. Bandsma M. Ouwens Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes 52 5 2003 1081 1089
31. M. Sekiya N. Yahagi T. Matsuzaka Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 38 6 2003 1529 1539
32. G. Svegliati-Baroni g.svegliati@univpm.it C. Candelaresi S. Saccomanno A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-α and n-3 polyunsaturated fatty acid treatment on liver injury. American Journal of Pathology 169 3 2006 846 860
33. M. M. Haluzik Z. Lacinova M. Dolinkova Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-α agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 147 9 2006 4517 4524
34. T. Nagasawa tatsuya_nagasawa@pharm.kissei.co.jp Y. Inada S. Nakano Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. European Journal of Pharmacology 536 1-2 2006 182 191
35. Y. Harano K. Yasui T. Toyama Fenofibrate, a peroxisome proliferator-activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver International 26 5 2006 613 620
36. P. G. P. Martin H. Guillou F. Lasserre Novel aspects of PPARα-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study. Hepatology 45 3 2007 767 777
37. S. Kersten J. Seydoux J. M. Peters F. J. Gonzalez B. Desvergne W. Wahli walter.wahli@iba.unil.ch Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. Journal of Clinical Investigation 103 11 1999 1489 1498
38. T. C. Leone C. J. Weinheimer D. P. Kelly dkelly@imgate.wustl.edu A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proceedings of the National Academy of Sciences of the United States of America 96 13 1999 7473 7478
39. T. Hashimoto W. S. Cook C. Qi A. V. Yeldandi J. K. Reddy jkreddy@northwestern.edu M. S. Rao Defect in peroxisome proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. Journal of Biological Chemistry 275 37 2000 28918 28928
40. R. Stienstra S. Mandard D. Patsouris C. Maass S. Kersten M. Müller michael.muller@wur.nl Peroxisome proliferator-activated receptor α protects against obesity-induced hepatic inflammation. Endocrinology 148 6 2007 2753 2763
41. B. L. Knight brian.knight@csc.mrc.ac.uk A. Hebbachi D. Hauton A role for PPARα in the control of SREBP activity and lipid synthesis in the liver. Biochemical Journal 389 2 2005 413 421
42. T. Matsuzaka H. Shimano shimano-tky@umin.ac.jp N. Yahagi Dual regulation of mouse δ5- and δ6-desaturase gene expression by SREBP-1 and PPARα Journal of Lipid Research 43 1 2002 107 114
43. C. W. Miller J. M. Ntambi Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. Proceedings of the National Academy of Sciences of the United States of America 93 18 1996 9443 9448
44. I. J. Waterman V. A. Zammit Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. Diabetes 51 6 2002 1708 1713
45. P. Targett-Adams p.targett-adams@vir.gla.ac.uk M. J. McElwee E. Ehrenborg M. C. Gustafsson C. N. Palmer J. McLauchlan A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein. Biochimica et Biophysica Acta 1728 1-2 2005 95 104
46. B. Magnusson L. Asp P. Boström Adipocyte differentiation-related protein promotes fatty acid storage in cytosolic triglycerides and inhibits secretion of very low-density lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology 26 7 2006 1566 1571
47. A. C. Spósito R. C. Maranhão ramarans@usp.br C. G. C. Vinagre R. D. Santos J. A. F. Ramires Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. Atherosclerosis 154 2 2001 455 461
48. R. D. Santos L. I. Ventura A. C. Spósito R. Schreiber J. A. F. Ramires R. C. Maranhão ramarans@usp.br The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. Cardiovascular Research 49 2 2001 456 465
49. I. E. Simo J. A. Yakichuk T. C. Ooi Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis 100 1 1993 55 64
50. H. S. Simpson C. M. Williamson T. Olivecrona Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 85 2-3 1990 193 202
51. J.-P. Desager Y. Horsmans C. Vandenplas C. Harvengt Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis 124, supplement 1 1996 S65 S73
52. K. Schoonjans J. Peinado-Onsurbe A.-M. Lefebvre PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. The EMBO Journal 15 19 1996 5336 5348
53. B. Staels N. Vu-Dac V. A. Kosykh Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. Journal of Clinical Investigation 95 2 1995 705 712
54. J.-M. Bard H.-J. Parra R. Camare A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 41 5 1992 498 503
55. A. Minnich anne.minnich@aventis.com N. Tian L. Byan G. Bilder A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle. American Journal of Physiology 280 2 2001 E270 E279
56. I. Lemieux H. Salomon J.-P. Després jean-pierre.despres@crhl. ulaval.ca Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients. Annals of Medicine 35 6 2003 442 448
57. E. Raspé H. Duez A. Mansén Identification of Rev-erbα as a physiological repressor of apoC-III gene transcription. Journal of Lipid Research 43 12 2002 2172 2179
58. P. Gervois S. Chopin-Delannoy A. Fadel Fibrates increase human Rev-erbα expression in liver via a novel peroxisome proliferator-activated receptor response element. Molecular Endocrinology 13 3 1999 400 409
59. R. Hertz J. Bishara-Shieban J. Bar-Tana Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. Journal of Biological Chemistry 270 22 1995 13470 13475
60. S. Qu D. Su J. Altomonte PPARα mediates the hypolipidemic action of fibrates by antagonizing FoxO1. American Journal of Physiology 292 2 2007 E421 E434
61. A. E. Schultze W. E. Alborn R. K. Newton R. J. Konrad konrad_robert@lilly.com Administration of a PPARα agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio. Journal of Lipid Research 46 8 2005 1591 1595
62. X. Prieur H. Coste J. C. Rodríguez jcrodrig@freesurf.fr The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-α and contains a novel farnesoid X-activated receptor response element. Journal of Biological Chemistry 278 28 2003 25468 25480
63. N. Vu-Dac Ngoc.vu-dac@pasteur-lille.fr P. Gervois H. Jakel Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor α activators. Journal of Biological Chemistry 278 20 2003 17982 17985
64. S. Kersten S. Mandard N. S. Tan Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. Journal of Biological Chemistry 275 37 2000 28488 28493
65. K. Yoshida T. Shimizugawa M. Ono H. Furukawa furuka@shina.sankyo.co.jp Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. Journal of Lipid Research 43 11 2002 1770 1772
66. S. Mandard F. Zandbergen N. S. Tan The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. Journal of Biological Chemistry 279 33 2004 34411 34420
67. S. Mandard F. Zandbergen E. van Straten The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. Journal of Biological Chemistry 281 2 2006 934 944
68. A. Köster koester_anja@lilly.com Y. B. Chao M. Mosior Transgenic angiopoietin-like (ANGPTL)4 overexpression and targeted disruption of ANGPTL4 and ANGPTL3: regulation of triglyceride metabolism. Endocrinology 146 11 2005 4943 4950
69. X. Yu S. C. Burgess H. Ge Inhibition of cardiac lipoprotein utilization by transgenic overexpression of ANGPTL4 in the heart. Proceedings of the National Academy of Sciences of the United States of America 102 5 2005 1767 1772
70. U. Desai E.-C. Lee K. Chung Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proceedings of the National Academy of Sciences of the United States of America 104 28 2007 11766 11771
71. S. Romeo L. A. Pennacchio Y. Fu Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nature Genetics 39 4 2007 513 516
72. V. Sukonina A. Lookene T. Olivecrona G. Olivecrona gunilla. olivecrona@medbio.umu.se Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proceedings of the National Academy of Sciences of the United States of America 103 46 2006 17450 17455
73. J. M. Odonkor M. P. Rogers Effects of ethyl-CPIB (clofibrate) on tissue lipoprotein lipase and plasma post-heparin lipolytic activity in rats. Biochemical Pharmacology 33 8 1984 1337 1341
74. A. V. M. Ferreira G. G. Parreira A. Green L. M. Botion botion@icb.ufmg.br Effects of fenofibrate on lipid metabolism in adipose tissue of rats. Metabolism 55 6 2006 731 735
75. F. G. Gbaguidi G. Chinetti D. Milosavljevic Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages. FEBS Letters 512 1-3 2002 85 90
76. R. Carroll D. L. Severson severson@ucalgary.ca Peroxisome proliferator-activated receptor-α ligands inhibit cardiac lipoprotein lipase activity. American Journal of Physiology 281 2 2001 H888 H894
77. R. S. Birjmohun r.s.birjmohun@amc.uva.nl B. A. Hutten J. J. P. Kastelein E. S. G. Stroes Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. Journal of the American College of Cardiology 45 2 2005 185 197
78. B. Staels A. van Tol T. Andreu J. Auwerx Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arteriosclerosis and Thrombosis 12 3 1992 286 294
79. L. Berthou N. Duverger F. Emmanuel Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. Journal of Clinical Investigation 97 11 1996 2408 2416
80. N. Vu-Dac S. Chopin-Delannoy P. Gervois The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erbα mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. Journal of Biological Chemistry 273 40 1998 25713 25720
81. N. Vu-Dac K. Schoonjans V. Kosykh Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. Journal of Clinical Investigation 96 2 1995 741 750
82. J. M. Timmins J.-Y. Lee E. Boudyguina Targeted inactivation of hepatic ABCA1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. Journal of Clinical Investigation 115 5 2005 1333 1342
83. L. R. Brunham J. K. Kruit J. Iqbal Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. Journal of Clinical Investigation 116 4 2006 1052 1062
84. L. R. Brunham R. R. Singaraja M. R. Hayden Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annual Review of Nutrition 26 2006 105 129
85. J. McNeish R. J. Aiello D. Guyot High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proceedings of the National Academy of Sciences of the United States of America 97 8 2000 4245 4250
86. E. Orsó C. Broccardo W. E. Kaminski Transport of lipids from Golgi to plasma membrane is defective in tangier disease patients and ABC1-deficient mice. Nature Genetics 24 2 2000 192 196
87. B. L. Knight brian.knight@csc.mrc.ac.uk D. D. Patel S. M. Humphreys D. Wiggins G. F. Gibbons Inhibition of cholesterol absorption associated with a PPARα -dependent increase in ABC binding cassette transporter A1 in mice. Journal of Lipid Research 44 11 2003 2049 2058
88. G. Chinetti S. Lestavel V. Bocher PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 7 1 2001 53 58
89. J. J. Repa S. D. Turley J.-M. A. Lobaccaro Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289 5484 2000 1524 1529
90. N. Wang nw30@columbia.edu D. Lan W. Chen F. Matsuura A. R. Tall ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proceedings of the National Academy of Sciences of the United States of America 101 26 2004 9774 9779
91. B. Staels A. van Tol G. Skretting J. Auwerx Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates. Journal of Lipid Research 33 5 1992 727 735
92. M. Bouly D. Masson B. Gross Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. Journal of Biological Chemistry 276 28 2001 25841 25847
93. C. C. van der Hoogt W. de Haan M. Westerterp Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. Journal of Lipid Research 48 8 2007 1763 1771
94. P. Mardones A. Pilon M. Bouly Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. Journal of Biological Chemistry 278 10 2003 7884 7890
95. J. N. van der Veen j.n.van.der.veen@med.rug.nl J. K. Kruit R. Havinga Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1. Journal of Lipid Research 46 3 2005 526 534
96. W. R. Oliver Jr. J. L. Shenk M. R. Snaith A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences of the United States of America 98 9 2001 5306 5311
97. D. L. Sprecher dennis.l.sprecher@gsk.com C. Massien G. Pearce Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arteriosclerosis, Thrombosis, and Vascular Biology 27 2 2007 359 365
98. T. E. Akiyama G. Lambert C. J. Nicol Peroxisome proliferator-activated receptor β/δ regulates very low density lipoprotein production and catabolism in mice on a Western diet. Journal of Biological Chemistry 279 20 2004 20874 20881
99. J. Berger joel_berger@merck.com M. D. Leibowitz T. W. Doebber Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects. Journal of Biological Chemistry 274 10 1999 6718 6725
100. A.-M. Lefebvre J. Peinado-Onsurbe I. Leitersdorf Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arteriosclerosis, Thrombosis, and Vascular Biology 17 9 1997 1756 1764
101. S. Sunayama snym@med.juntendo.ac.jp Y. Watanabe H. Ohmura Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 146 1 1999 187 193
102. J. Kobayashi I. Nagashima M. Hikita Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. British Journal of Clinical Pharmacology 47 4 1999 433 439
103. K. Shirai kshirai@kb3.so-net.ne.jp Y. Itoh H. Sasaki The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Research and Clinical Practice 46 1 1999 35 41
104. A. Tailleux G. Torpier H. Mezdour J.-C. Fruchart B. Staels C. Fiévet Catherine.Fievet@pasteur-lille.fr Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Trends in Pharmacological Sciences 24 10 2003 530 534
105. J. P. H. van Wijk j.p.h.vanwijk@azu.nl E. J. P. de Koning M. Castro Cabezas T. J. Rabelink Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 28 4 2005 844 849
106. G. D. Tan garry.tan@oxlip.ox.ac.uk B. A. Fielding J. M. Currie The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48 1 2005 83 95
107. R. B. Goldberg rgoldber@med.miami.edu Impact of thiazolidenediones on serum lipoprotein levels. Current Atherosclerosis Reports 8 5 2006 397 404
108. K. Nagashima C. Lopez D. Donovan Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. Journal of Clinical Investigation 115 5 2005 1323 1332
109. I. Bogacka bogackiu@pbrc.edu H. Xie G. A. Bray S. R. Smith The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo. Diabetes Care 27 7 2004 1660 1667
110. M. Tiikkainen A.-M. Häkkinen E. Korsheninnikova T. Nyman S. Mäkimattila H. Yki-Järvinen ykijarvi@helsinki.fi Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 8 2004 2169 2176
111. M. Laplante H. Sell K. L. MacNaul D. Richard J. P. Berger Y. Deshaies yves.deshaies@phs.ulaval.ca PPAR-γ activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52 2 2003 291 299
112. M. Laplante W. T. Festuccia G. Soucy Mechanisms of the depot specificity of peroxisome proliferator-activated receptor γ action on adipose tissue metabolism. Diabetes 55 10 2006 2771 2778
113. H. Kageyama T. Hirano hirano@med.showa-u.ac.jp K. Okada Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-γ Biochemical and Biophysical Research Communications 305 1 2003 22 27
114. S. Ranganathan P. A. Kern KernPhilipA@exchange.UAMS.edu Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes. Journal of Biological Chemistry 273 40 1998 26117 26122
115. A. Xu amxu@hkucc.hku.hk M. C. Lam K. W. Chan Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proceedings of the National Academy of Sciences of the United States of America 102 17 2005 6086 6091
116. G. Medina-Gomez S. L. Gray L. Yetukuri PPAR γ 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genetics 3 4 2007 e64
117. J. R. Jones C. Barrick K.-A. Kim Deletion of PPARγ in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 102 17 2005 6207 6212
118. A. Gauthier G. Vassiliou F. Benoist R. McPherson rmcpherson@ottawaheart. ca Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor γ Journal of Biological Chemistry 278 14 2003 11945 11953
119. R. B. Goldberg D. M. Kendall M. A. Deeg A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 7 2005 1547 1554
120. S. E. Kahn skahn@u.washington.edu S. M. Haffner M. A. Heise Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England Journal of Medicine 355 23 2006 2427 2443
121. J. A. Dormandy john.dormandy@btinternet.com B. Charbonnel D. J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. The Lancet 366 9493 2005 1279 1289
122. E. Chiquette G. Ramirez R. DeFronzo albarado@uthscsa.edu A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Archives of Internal Medicine 164 19 2004 2097 2104
123. A. Chawla W. A. Boisvert C.-H. Lee A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Molecular Cell 7 1 2001 161 171